Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients

International Journal of Antimicrobial Agents

Volumn 48, Issue 4, 2016, Pages 415-421

  Yunivita, Vycke ^a   Dian, Sofiati ^a   Ganiem, Ahmad Rizal ^a   Hayati, Ela ^a   Hanggono Achmad, Tri ^a   Purnama Dewi, Atu ^a   Teulen, Marga ^b   Meijerhof Jager, Petra ^b   van Crevel, Reinout ^b   Aarnoutse, Rob ^b   Ruslami, Rovina ^a  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Indonesia; Pharmacokinetics; Rifampicin; Tolerability; Tuberculous meningitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; INDONESIAN; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT WITHDRAWAL; TUBERCULOUS MENINGITIS; VOMITING; ADOLESCENT; CHEMISTRY; INDONESIA; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLASMA; RANDOMIZATION; TIME FACTOR; TOXIC HEPATITIS; TUBERCULOSIS, MENINGEAL; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTITUBERCULAR; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HUMANS; INDONESIA; MALE; MIDDLE AGED; PLASMA; RANDOM ALLOCATION; RIFAMPIN; TIME FACTORS; TUBERCULOSIS, MENINGEAL; YOUNG ADULT;

EID: 84988517588     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.06.016     Document Type: Article

References (22)

1. [1] World Health Organization, Global tuberculosis report 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf, 2013 accessed 20.07.16.
2. [2] Thwaites, G.E., van Toorn, R., Schoeman, J., Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 12 (2013), 999–1010.
3. [3] Begley, D.J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104 (2004), 29–45.
4. [4] Donald, P.R., Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 90 (2010), 279–292.
5. [5] Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B.L., Mahesh, B.N., Jayashree, R., et al. Pharmacokinetics–pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47 (2003), 2118–2124.
6. [6] de Steenwinkel, J.E., Aarnoutse, R.E., de Knegt, G.J., ten Kate, M.T., Teulen, M., Verbrugh, H.A., et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med 187 (2013), 1127–1134.
7. [7] Steingart, K.R., Jotblad, S., Robsky, K., Deck, D., Hopewell, P.C., Huang, D., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 15 (2011), 305–316.
8. [8] van Ingen, J., Aarnoutse, R.E., Donald, P.R., Diacon, A.H., Dawson, R., van Plemper, B.G., et al. Why do we use 600 mg of rifampicin in tuberculosis treatment?. Clin Infect Dis 52 (2011), e194–9.
9. [9] Ruslami, R., Ganiem, A.R., Dian, S., Apriani, L., Achmad, T.H., van der Ven, A.J., et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13 (2013), 27–35.
10. [10] Marais, S., Thwaites, G., Schoeman, J.F., Török, M.E., Misra, U.K., Prasad, K., et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 10 (2010), 803–812.
11. [11] Thwaites, G.E., Nguyen, D.B., Nguyen, H.D., Hoang, T.Q., Do, T.T., Nguyen, T.C., et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351 (2004), 1741–1751.
12. [12] Ruslami, R., Nijland, H.M., Alisjahbana, B., Parwati, I., van Crevel, R., Aarnoutse, R.E., Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51 (2007), 2546–2551.
13. [13] Ruslami, R., Nijland, H.M., Adhiarta, I.G., Kariadi, S.H., Alisjahbana, B., Aarnoutse, R.E., et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 54 (2010), 1068–1074.
14. [14] Acocella, G., Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3 (1978), 108–127.
15. [15] van Crevel, R., Nelwan, R.H., Borst, F., Sahiratmadja, E., Cox, J., van der Meij, W., et al. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers. Int J Tuberc Lung Dis 8 (2004), 500–503.
16. [16] Te Brake, L., Dian, S., Ganiem, A.R., Ruesen, C., Burger, D., Donders, R., et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 45 (2015), 496–503.
17. [17] Acocella, G., Segre, G., Conti, R., Pagani, V., Pallanza, R., Perna, G., et al. Pharmacokinetic study on intravenous rifampicin in man. Pharmacol Res Commun 16 (1984), 723–736.
18. [18] Pasipanodya, J., Gumbo, T., An oracle: antituberculosis pharmacokinetics–pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 55 (2011), 24–34.
19. [19] Boeree, M.J., Diacon, A.H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., et al. PanACEA Consortium. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 191 (2015), 1058–1065.
20. [20] Boeree, M., Hoelscher, M., PanACEA Consortium. High-dose rifampin, SQ109 and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. In: 22nd Conference on Retroviruses and Opportunistic Infections (CROI); 23–26 February 2015; Seattle, WA, 2015.
21. [21] Heemskerk, A.D., Bang, N.D., Mai, N.T., Chau, T.T., Phu, N.H., Loc, P.P., et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med 374 (2016), 124–134.
22. [22] van Crevel, R., Ruslami, R., Aarnoutse, R., High dose rifampicin for tuberculous meningitis in Vietnam: high enough?. N Engl J Med, 374, 2016, 2187.